Page breadcrumb nav

VAERS Report 2157096

Case Report Section

Vaer Report Details

Age: NA

Gender: Male

State: Outside US

Patient Died?
No
Vaccine information

Name: COVID19 (COVID19 (JANSSEN))

Type: Coronavirus 2019 vaccine

Manufacturer: JANSSEN

Lot: unknown


Date report was received
2022-03-04
Date form completed
Date Vaccinated
Date of Onset
0
Number of days (onset date – vaccination date)
0
Adverse Event Description

guillain-barre-syndrome; fulminant encephalomyelitis; this spontaneous report was received from literature. this report concerned a 47 year old male of an unspecified race and ethnicity. the patient's weight, height, and medical history (unremarkable medical history) were not reported. it was noted the patient was previously healthy. the patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for drug use for prophylactic vaccination. no concomitant medications were reported. on an unspecified date, 28 days after immunization the patient experienced guillain-barre-syndrome and fulminant encephalomyelitis, and was hospitalized (date unspecified). the patient presented at hospital with with acral paresthesias and ascending flaccid paraparesis, 28 days after immunization with ad26.cov2.s. guillain-barre-syndrome was diagnosed based on findings of cytoalbuminologic dissociation (csf protein: 5.6 g/l; cells: 2/mm3), negative infectious work-up (including csf gram-staining, multiplexed csf filmarray� polymerase chain reaction [pcr] meningitis/ encephalitis panel, sars-cov-2 pcr, and serological screening for syphilis, hiv, and htlv1/2), absence of systemic inflammatory markers (normal c-reactive protein levels and normal white blood cell count), and electrophysiological evidence of prolonged f responses and abolished h-reflexes. the patient received treatment with intravenous immunoglobulin (2 gr/kg) with substantial improvement of his neurological symptoms. one week later, during the course of hospitalization, the patient deteriorated rapidly, developing a new t6-sensory-level and a severe tetraparesis (1/5 and 4/5 motor strength in the resource scale in the lower and upper extremities, respectively). upon clinical deterioration, magnetic resonance imaging (mri) of the neuroaxis was performed, revealing striking neuroimaging findings which were compatible with a fulminant encephalomyelitis. the mri scan also showed coronal t2-weighted hyperintense signal along the corticospinal tracts bilaterally ("wine glass" sign). a hyperintense lesion is shown in the left middle cerebellar peduncle. no contrast enhancing lesions or lesions with diffusion restriction were depicted, while the optic nerves had normal appearance. c sagittal t2-weighted spine mri showed longitudinally extensive thoracolumbar spinal cord lesions, with combined gray/white-matter involvement, affecting more than two-thirds of the thoracic spinal cord's cross-sectional area. findings compatible with transverse myelitis. further antibody and ocb testing was not performed because the patient declined additional investigations. the patient received treatment with intravenous methylprednisolone (5gr) with gradual improvement of his motor and sensory symptoms. he was discharged with a mild residual paraparesis (4/5 and 5/5 muscle strength in the lower and upper extremities. the action taken with covid-19 vaccine ad26.cov2.s was not applicable. the patient was recovering from guillain-barre-syndrome and fulminant encephalomyelitis. this report was serious (hospitalization caused / prolonged).; sender's comments: v0: this spontaneous report that was received from literature concerned a 47-year-old man of an unknown race and ethnicity who experienced gbs and fulminant encephalomyelitis 28 days after vaccine. no past medical history and concomitant medications were reported. on an unspecified date patient presented at hospital with acral paresthesias and ascending flaccid paraparesis. laboratory data included cytoalbuminologic dissociation (csf protein: 5.6 g/l; cells: 2/mm3), negative infectious work-up, absence of systemic inflammatory markers (normal crp levels and normal wbc count), electrophysiological evidence of prolonged f responses and abolished h-reflexes confirmed the diagnosis of gbs. the patient received treatment with ivig and there was a substantial improvement in his neurological symptoms. one week later, during the course of hospitalization, the patient deteriorated rapidly, developing a new t6-sensory-level and a severe tetraparesis. upon clinical deterioration, mri of the neuroaxis was performed, revealing striking neuroimaging findings which were compatible with a fulminant encephalomyelitis. further antibody and ocb testing was not performed because the patient declined additional investigations. the patient received treatment with intravenous methylprednisolone (5gr/kg) with gradual improvement of his motor and sensory symptoms. he was discharged with a mild residual paraparesis (4/5 and 5/5 muscle strength in the lower and upper extremities. however, the patient was recovering from gbs and fulminant encephalomyelitis, the temporal relationship with the vaccine cannot be ruled out and the events are assessed to have an indeterminate relationship with vaccination

Lab Data
test name: csf protein; result unstructured data: 5.6 g/l; test name: csf culture negative; result unstructured data: see relevant lab tests; test name: pcr; result unstructured data: meningitis / encephalitis panel negative; test name: sars-cov-2 test negative; result unstructured data: negative pcr; test name: magnetic resonance imaging; result unstructured data: see relevant lab tests; comments: mri compatible with a fulminant encephalomyelitis. coronal t2-weighted mri displays hyperintense signal along the corticospinal tracts bilaterally ("wine glass" sign). a hyperintense lesion is shown in the left middle cerebellar peduncle. no contrast enhancing lesions or lesions with diffusion restriction were depicted, while the optic nerves had normal appearance. sagittal t2-weighted spine mri showed longitudinally extensive thoracolumbar spinal cord lesions, with combined gray/white-matter involvement, affecting more than two-thirds of the thoracic spinal cord's cross-sectional area. findings compatible with transverse myelitis.; test name: hiv infection; result unstructured data: negative; test name: c-reactive protein; result unstructured data: normal; test name: white blood cell count; result unstructured data: normal; test name: syphilis; result unstructured data: negative
List of symptoms
sars-cov-2 test negative syphilis guillain-barre syndrome polymerase chain reaction white blood cell count hiv infection magnetic resonance imaging c-reactive protein csf culture negative encephalomyelitis csf protein
Patient Died?
No
Date Died
NA
Birth defect
false
Vaccine Administered By:
Other
Vaccine Purchased By:
Unknown
Patient visit ER?
No
Patient Hospitalized?
Yes
Stay in hospital
No
Days in hospital
Unspecified
Permanent disability?
No
Allergies:
na
Current Illness
na